Find a Clinical Trial
With our more than 160 cancer researchers and physicians working together, we’re making scientific discoveries that translate into better treatments and better health for our patients. In fact, some of our treatments are used in hospitals around the country and the world.
If you’re a current patient, the first step is to talk to your doctor about trials that you might be eligible for. Keep in mind that we open new trials often, so check the clinical trials directory below for a complete list of active studies.
If you and your doctor decide a clinical trial is best, a UAMS research team that includes doctors, nurses, social workers, dietitians, and other health care professionals will work with you. They will provide your care, monitor your health carefully, and give you specific instructions about the study.
Clinical Trial Questions?
Call 501-686-8288 or email CancerClinicalTrials@uams.edu
Breast Cancer Focus Group Participants Needed
We are looking for young African American/Black women (ages 18 – 45) who completed breast cancer treatment in the last 5 years.
Learn MoreFeatured Clinical Trials
UAMS Contributes to Groundbreaking Lung Cancer Clinical Trial
The long-awaited results of a 10-year lung cancer clinical trial that UAMS contributed to were recently published in the New England Journal of Medicine.
Read more
Can a Second Chemotherapy Drug in Addition to Standard Radiation and Temozolomide Extend Your Life or Prevent the Growth and Spread of Your Brain Tumor?
NRG-BN011 is a phase II trial will be testing if the addition of Lomustine (Gleostine) to the usual treatment of temozolomide and radiotherapy improves outcomes for patients with newly diagnosed MGMT methylated glioblastoma who have not received treatment other than surgery for their disease.
Read more
Does adding a study drug to usual therapy after radical prostatectomy delay the spread of prostate cancer?
The NRG-GU008 trial (the “INNOVATE” study) is a phase III study for patients with node-positive prostate cancer and need further treatment after their prostatectomy. This trial is testing if the addition of apalutamide to the usual hormone therapy with radiotherapy improves outcomes for patients.
Read more
Phase 1 Clinical Trial Tests Monoclonal Antibody + PD-1 Inhibitor
Led by Michael Birrer, M.D., Ph.D., Cancer Institute director, this study will bring a novel approach of harnessing the body’s immune system to treat cancer patients who have failed multiple lines of chemo and immunotherapies.
Read more